Jian-Hua Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jian-Hua Hong has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Yu-Chuan Lu
Institute of Biomedical Engineering, National Taiwan University, Taipei City, Taiwan
8 shared publicationsKuo-How Huang
Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
7 shared publicationsChao-Yuan Huang
Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
5 shared publicationsYeong-Shiau Pu
Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
5 shared publications- Chao-Yuan Huang
Department of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan
4 shared publications Chung-Hsin Chen
Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
4 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Comparing the clinical outcomes and learning curves of prostatic urethral lift performed by experienced versus naïve urologists
Purpose To characterize the learning process by comparing the clinical outcomes and learning curves of prostatic urethral lift (PUL) performed by experienced versus naïve urologists. Methods Consecutive patients treated with PUL at a tertiary center by an experienced urologist with > 100 PUL cases or by naïve urologists with no prior PUL experience were included in this study. Perioperative parameters, functional outcomes, complications, and retreatment rates were compared. Learning curves were assessed using the cumulative sum (CUSUM) methodology. Multivariate regression identified predictors of operative time. Results The median operative time was 20.0 min in both groups. Overall, the International Prostate Symptoms Score total decreased by a median of 9.0 points, quality of life score decreased by a median of 2.0 points, peak urinary flow rate increased by a median of 4.3 ml/sec, and post-void residual volume decreased by a median of 19.8 ml. There were no significant differences between the two groups in functional outcomes, complication rate, or operative time. CUSUM analysis revealed a three-phase learning curve, with proficiency achieved after 5 to 8 cases. Operative time was independently associated with obstructive median lobe (P = 0.003), number of implants (P = 0.005), implant deployment failure (P < 0.001), and experience (P = 0.024). Conclusion PUL can be safely and effectively performed by both experienced and naïve urologists with comparable outcomes. The learning curve is short but defined with proficiency achieved after 5 to 8 cases.
- 2 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Open AccessComparing the clinical outcomes and learning curves of prostatic urethral lift performed by experienced versus naïve urologists
Purpose To characterize the learning process by comparing the clinical outcomes and learning curves of prostatic urethral lift (PUL) performed by experienced versus naïve urologists. Methods Consecutive patients treated with PUL at a tertiary center by an experienced urologist with > 100 PUL cases or by naïve urologists with no prior PUL experience were included in this study. Perioperative parameters, functional outcomes, complications, and retreatment rates were compared. Learning curves were assessed using the cumulative sum (CUSUM) methodology. Multivariate regression identified predictors of operative time. Results The median operative time was 20.0 min in both groups. Overall, the International Prostate Symptoms Score total decreased by a median of 9.0 points, quality of life score decreased by a median of 2.0 points, peak urinary flow rate increased by a median of 4.3 ml/sec, and post-void residual volume decreased by a median of 19.8 ml. There were no significant differences between the two groups in functional outcomes, complication rate, or operative time. CUSUM analysis revealed a three-phase learning curve, with proficiency achieved after 5 to 8 cases. Operative time was independently associated with obstructive median lobe (P = 0.003), number of implants (P = 0.005), implant deployment failure (P < 0.001), and experience (P = 0.024). Conclusion PUL can be safely and effectively performed by both experienced and naïve urologists with comparable outcomes. The learning curve is short but defined with proficiency achieved after 5 to 8 cases.
- Open Access
- 30 September 2024
- Published by Wolters Kluwer Health in Urological Science
- Vol. 35 (3) , 103-111
Updated clinical evidence and molecular features of antibody-drug conjugates for advanced urothelial carcinoma
Platinum-based chemotherapy and immunotherapy are the primary systemic treatments for patients with advanced urothelial carcinoma (UC). However, the efficacy of these systemic therapies has yet to be optimized. Antibody-drug conjugates (ADCs), which combine the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs, have emerged as a promising new class of targeted therapies for UC. Currently, the Food and Drug Administration has approved 2 ADCs, namely Padcev and Trodelvy, for the treatment of advanced UC. This review provides an overview of the clinical evidence supporting the use of ADCs in patients with UC and summarizes the molecular features underlying these ADCs, which could be essential for understanding resistance mechanisms and minimizing treatment-related adverse events.
- 30 September 2024
- Published by Wolters Kluwer Health in Urological Science
- Vol. 35 (3) , 103-111
Open AccessUpdated clinical evidence and molecular features of antibody-drug conjugates for advanced urothelial carcinoma
Platinum-based chemotherapy and immunotherapy are the primary systemic treatments for patients with advanced urothelial carcinoma (UC). However, the efficacy of these systemic therapies has yet to be optimized. Antibody-drug conjugates (ADCs), which combine the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs, have emerged as a promising new class of targeted therapies for UC. Currently, the Food and Drug Administration has approved 2 ADCs, namely Padcev and Trodelvy, for the treatment of advanced UC. This review provides an overview of the clinical evidence supporting the use of ADCs in patients with UC and summarizes the molecular features underlying these ADCs, which could be essential for understanding resistance mechanisms and minimizing treatment-related adverse events.
- Open Access
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42 (3) , 587-599
Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors
Hong JH, et al. World J Mens Health. 2023 Sep;41:e76. https://doi.org/10.5534/wjmh.230107
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42 (3) , 587-599
Open AccessActive Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors
Hong JH, et al. World J Mens Health. 2023 Sep;41:e76. https://doi.org/10.5534/wjmh.230107
- Open Access
- 21 July 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
To compare clinical outcomes between the use of robotic-assisted laparoscopic radical prostatectomy (RP) and radiotherapy (RT) with long-term androgen deprivation therapy (ADT) in locally advanced prostate cancer (PC), 315 patients with locally advanced PC (clinical T-stage 3/4) were considered for analysis retrospectively. Propensity score-matching at a 1:1 ratio was performed. The median follow-up period was 59.2 months (IQR 39.8–87.4). There were 117 (37.1%) patients in the RP group and 198 (62.9%) patients in the RT group. RT patients were older and had higher PSA at diagnosis, higher Gleason score grade group and more advanced T-stage (all p < 0.001). After propensity score-matching, there were 68 patients in each group. Among locally advanced PC patients, treatment with RP had a higher risk of biochemical recurrence compared to the RT group. In multivariate Cox regression analysis, treatment with RT plus ADT significantly decreased the risk of biochemical failure (HR 0.162, p < 0.001), but there was no significant difference in local recurrence, distant metastasis and overall survival (p = 0.470, p = 0.268 and p = 0.509, respectively). This information supported a clinical benefit in BCR control for patients undergoing RT plus long-term ADT compared to RP.
- 21 July 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Open AccessPropensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
To compare clinical outcomes between the use of robotic-assisted laparoscopic radical prostatectomy (RP) and radiotherapy (RT) with long-term androgen deprivation therapy (ADT) in locally advanced prostate cancer (PC), 315 patients with locally advanced PC (clinical T-stage 3/4) were considered for analysis retrospectively. Propensity score-matching at a 1:1 ratio was performed. The median follow-up period was 59.2 months (IQR 39.8–87.4). There were 117 (37.1%) patients in the RP group and 198 (62.9%) patients in the RT group. RT patients were older and had higher PSA at diagnosis, higher Gleason score grade group and more advanced T-stage (all p < 0.001). After propensity score-matching, there were 68 patients in each group. Among locally advanced PC patients, treatment with RP had a higher risk of biochemical recurrence compared to the RT group. In multivariate Cox regression analysis, treatment with RT plus ADT significantly decreased the risk of biochemical failure (HR 0.162, p < 0.001), but there was no significant difference in local recurrence, distant metastasis and overall survival (p = 0.470, p = 0.268 and p = 0.509, respectively). This information supported a clinical benefit in BCR control for patients undergoing RT plus long-term ADT compared to RP.
- Open Access
- 29 December 2021
- Published by Springer Nature in Research Square
Clinical Outcomes in Locally Advanced Prostate Cancer Between Radical Prostatectomy and Radiotherapy With Androgen Deprivation Therapy: A Propensity Score-matched Analysis
To compare clinical outcomes between the use of robotic-assisted laparoscopic radical prostatectomy (RP) and radiotherapy (RT) with long-term androgen deprivation therapy (ADT) in locally advanced prostate cancer (PC), we enrolled 315 patients with locally advanced PC (clinical T-stage 3/4). Propensity score-matching at a 1:1 ratio was performed. The median follow-up period was 59.2 months (IQR: 39.8-87.4). There were 117 (37.1%) patients in the RP group and 198 (62.9%) patients in the RT group. RT patients were older and had higher PSA at diagnosis, higher Gleason score grade group and more advanced T-stage (all ppp=0.470, p=0.268 and p=0.509, respectively). This information may provide insight for clinicians and patients for decision-making regarding their preference for either treatment strategy.
- 29 December 2021
- Published by Springer Nature in Research Square
Open AccessClinical Outcomes in Locally Advanced Prostate Cancer Between Radical Prostatectomy and Radiotherapy With Androgen Deprivation Therapy: A Propensity Score-matched Analysis
To compare clinical outcomes between the use of robotic-assisted laparoscopic radical prostatectomy (RP) and radiotherapy (RT) with long-term androgen deprivation therapy (ADT) in locally advanced prostate cancer (PC), we enrolled 315 patients with locally advanced PC (clinical T-stage 3/4). Propensity score-matching at a 1:1 ratio was performed. The median follow-up period was 59.2 months (IQR: 39.8-87.4). There were 117 (37.1%) patients in the RP group and 198 (62.9%) patients in the RT group. RT patients were older and had higher PSA at diagnosis, higher Gleason score grade group and more advanced T-stage (all ppp=0.470, p=0.268 and p=0.509, respectively). This information may provide insight for clinicians and patients for decision-making regarding their preference for either treatment strategy.
- Open Access
- 23 June 2020
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 120 (1) , 483-491
Association between low prostate-specific antigen levels and greater disease progression in high-grade locally-advanced prostate cancer
- 23 June 2020
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 120 (1) , 483-491
Open AccessAssociation between low prostate-specific antigen levels and greater disease progression in high-grade locally-advanced prostate cancer
- Open Access
- 21 January 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-7
Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy
To evaluate the predictive accuracy of the %p2PSA and prostate health index (PHI) in predicting aggressive pathological outcomes in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP), we enrolled 91 patients with organ-confined PCa who were treated with robot-assisted RP. p2PSA levels and the PHI were investigated for their ability to predict pathological results. The %p2PSA and PHI were both significantly higher in patients with ≥pT3 disease, high-risk disease, positive surgical margin, or seminal vesical invasion (SVI). In univariable analysis, p2PSA derivatives were significant predictors of the presence of ≥pT3 disease, high-risk disease, positive surgical margin, and SVI. To predict adverse pathological outcomes at a sensitivity of 90%, p2PSA derivatives had higher specificity than standard PSA derivatives. In multivariable analysis, additional increases in the area under the receiver operating characteristic curve (AUC) were observed with the %p2PSA and PHI for ≥pT3 disease, high-risk disease, and positive surgical margin (8.2% and 2.7%, 6.2% and 4.1%, and 8.6% and 5.4%, respectively). A PHI ≥61.26 enhanced the predictive accuracy of the model for SVI by increasing the AUC from 0.624 to 0.819 (p = 0.009). The preoperative %p2PSA and PHI accurately predict adverse pathological results and are useful for decision-making.
- 21 January 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-7
Open AccessPreoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy
To evaluate the predictive accuracy of the %p2PSA and prostate health index (PHI) in predicting aggressive pathological outcomes in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP), we enrolled 91 patients with organ-confined PCa who were treated with robot-assisted RP. p2PSA levels and the PHI were investigated for their ability to predict pathological results. The %p2PSA and PHI were both significantly higher in patients with ≥pT3 disease, high-risk disease, positive surgical margin, or seminal vesical invasion (SVI). In univariable analysis, p2PSA derivatives were significant predictors of the presence of ≥pT3 disease, high-risk disease, positive surgical margin, and SVI. To predict adverse pathological outcomes at a sensitivity of 90%, p2PSA derivatives had higher specificity than standard PSA derivatives. In multivariable analysis, additional increases in the area under the receiver operating characteristic curve (AUC) were observed with the %p2PSA and PHI for ≥pT3 disease, high-risk disease, and positive surgical margin (8.2% and 2.7%, 6.2% and 4.1%, and 8.6% and 5.4%, respectively). A PHI ≥61.26 enhanced the predictive accuracy of the model for SVI by increasing the AUC from 0.624 to 0.819 (p = 0.009). The preoperative %p2PSA and PHI accurately predict adverse pathological results and are useful for decision-making.
- Open Access
- 2 October 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients
This study aimed to investigate the risks of thromboembolic vascular disease following androgen deprivation therapy (ADT) administered to prostate cancer (PCa) patients. A total of 24,464 men with newly diagnosed PCa during 2000–2008 were recruited through a longitudinal health insurance database in Taiwan. All PCa patients were stratified into two: ADT and non-ADT groups. Patients with ADT treatment were grouped into three: surgical castration, chemical castration, and anti-androgen alone. The risks of pulmonary embolism (PE), peripheral arterial occlusion disease (PAOD), and deep vein thrombosis (DVT) were assessed in multiple Cox proportional-hazards regression with time-dependent covariates. During the 12-year follow-up period, incidence rates per 1000 person-years in ADT and non-ADT groups were 2.87 and 1.62 for DVT, 1.00 and 0.52 for PE, and 1.03 and 0.70 for PAOD, respectively. The DVT and PE risks were significantly increased in patients receiving combined androgen blockade (CAB) compared with the counterpart ADT non-recipients. After adjusting for potential risk factors, PCa patients receiving CAB had the highest PE risk (HR = 3.11), followed by DVT risk (HR = 2.53). The DVT risk remained elevated throughout the entire duration of chemical castration. However, high PE risk was observed in patients with ≤720-day treatment duration. No association was found between ADT and PAOD risks. Overall, the risks of PE and DVT were considerably heightened in Asian men subjected to CAB for PCa, whereas PAOD risk was unrelated to such treatments.
- 2 October 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
Open AccessAssociations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients
This study aimed to investigate the risks of thromboembolic vascular disease following androgen deprivation therapy (ADT) administered to prostate cancer (PCa) patients. A total of 24,464 men with newly diagnosed PCa during 2000–2008 were recruited through a longitudinal health insurance database in Taiwan. All PCa patients were stratified into two: ADT and non-ADT groups. Patients with ADT treatment were grouped into three: surgical castration, chemical castration, and anti-androgen alone. The risks of pulmonary embolism (PE), peripheral arterial occlusion disease (PAOD), and deep vein thrombosis (DVT) were assessed in multiple Cox proportional-hazards regression with time-dependent covariates. During the 12-year follow-up period, incidence rates per 1000 person-years in ADT and non-ADT groups were 2.87 and 1.62 for DVT, 1.00 and 0.52 for PE, and 1.03 and 0.70 for PAOD, respectively. The DVT and PE risks were significantly increased in patients receiving combined androgen blockade (CAB) compared with the counterpart ADT non-recipients. After adjusting for potential risk factors, PCa patients receiving CAB had the highest PE risk (HR = 3.11), followed by DVT risk (HR = 2.53). The DVT risk remained elevated throughout the entire duration of chemical castration. However, high PE risk was observed in patients with ≤720-day treatment duration. No association was found between ADT and PAOD risks. Overall, the risks of PE and DVT were considerably heightened in Asian men subjected to CAB for PCa, whereas PAOD risk was unrelated to such treatments.
- Open Access
- 1 January 2018
- Published by Medknow in Urological Science
- Vol. 29 (3) , 136-144
Impact of High-Volume Disease in Asian Population with Newly Diagnosed Metastatic Prostate Cancer
Purpose: The purpose of this study is to investigate the clinical oncological outcomes and prognostic factors of high-volume disease (HVD) in the Asian population with metastatic hormone-sensitive prostate cancer. Methods: We retrospectively analyzed 503 patients with newly diagnosed metastatic prostate cancer. Patients were classified as HVD if visceral metastases were present and/or ≥4 bone lesions with ≥1 lesion beyond the vertebral bodies and pelvis. Overall survival (OS) and cancer-specific survival were investigated based on the disease burden. The Cox proportional hazards regression model was used to evaluate the prognostic factors. Results: About 50.7% patients were classified as low-volume disease (LVD) and 49.3% were HVD at diagnosis. The medians of OS and cancer-specific survival were 64 and 116 months, respectively, for patients with LVD and 26 and 46 months, respectively, for men with HVD (both P < 0.001). Among patients with HVD, 76.6% had both high-volume bone disease (HBD) (≥4 bone metastases) and appendicular bone involvement. There was no significant difference in both OS and cancer-specific survival between patients with visceral metastases and those with HBD combined with appendicular bone involvement. In the multivariable analysis, presence of Gleason score ≥8, HBD, or HVD may predict poorer OS and cancer-specific survival outcomes (all P < 0.05). Conclusions: Asian patients with high-volume metastatic prostate cancer had a larger proportion of HBD with appendicular bone involvement, who had a comparably poor prognosis to those with visceral metastases. Patients with HBD or HVD had reduced survival outcomes.
- 1 January 2018
- Published by Medknow in Urological Science
- Vol. 29 (3) , 136-144
Open AccessImpact of High-Volume Disease in Asian Population with Newly Diagnosed Metastatic Prostate Cancer
Purpose: The purpose of this study is to investigate the clinical oncological outcomes and prognostic factors of high-volume disease (HVD) in the Asian population with metastatic hormone-sensitive prostate cancer. Methods: We retrospectively analyzed 503 patients with newly diagnosed metastatic prostate cancer. Patients were classified as HVD if visceral metastases were present and/or ≥4 bone lesions with ≥1 lesion beyond the vertebral bodies and pelvis. Overall survival (OS) and cancer-specific survival were investigated based on the disease burden. The Cox proportional hazards regression model was used to evaluate the prognostic factors. Results: About 50.7% patients were classified as low-volume disease (LVD) and 49.3% were HVD at diagnosis. The medians of OS and cancer-specific survival were 64 and 116 months, respectively, for patients with LVD and 26 and 46 months, respectively, for men with HVD (both P < 0.001). Among patients with HVD, 76.6% had both high-volume bone disease (HBD) (≥4 bone metastases) and appendicular bone involvement. There was no significant difference in both OS and cancer-specific survival between patients with visceral metastases and those with HBD combined with appendicular bone involvement. In the multivariable analysis, presence of Gleason score ≥8, HBD, or HVD may predict poorer OS and cancer-specific survival outcomes (all P < 0.05). Conclusions: Asian patients with high-volume metastatic prostate cancer had a larger proportion of HBD with appendicular bone involvement, who had a comparably poor prognosis to those with visceral metastases. Patients with HBD or HVD had reduced survival outcomes.